Stay updated with breaking news from Kite therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BCMA-directed CAR T-cell therapy anitocabtagene autoleucel demonstrated a 76% complete remission rate and 89% negative minimal residual disease in patients with relapsed/refractory multiple myeloma. ....
Bristol Myers Squibb (BMY) could become a leader in cell therapy - a market that could be worth $50b within five years. Read about my thoughts on Century deal. ....
Roche bets big on off-the-shelf cancer cell therapy with Adaptimmune deal biopharmadive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharmadive.com Daily Mail and Mail on Sunday newspapers.